fapa catalog af3715 Search Results


fapa catalog af3715  (R&D Systems)
94
R&D Systems fapa catalog af3715
Fapa Catalog Af3715, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fapa catalog af3715/product/R&D Systems
Average 94 stars, based on 1 article reviews
fapa catalog af3715 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
fap α  (R&D Systems)
94
R&D Systems fap α
Z-GP-DAVLBH inhibits the proliferation of osteosarcoma cells in vitro . (A) The protein levels of <t>FAP</t> <t>α</t> in SJSA-1, 143B, hFOB 1.19 cells, and HBVPs were determined by Western blotting analysis. (B) SJSA-1, 143B, hFOB 1.19 cells, and HBVPs were treated with Z-GP-DAVLBH (10 μmol/L) in the presence or absence of TAL for 2 h. The hydrolysis efficiency of Z-GP-DAVLBH was analyzed by LC–MS. HBVPs serve as an FAP α -negative control cells. ND, no detection. (C) Osteosarcoma cells (SJSA-1 and 143B) were treated with various concentrations of Z-GP-DAVLBH for 24, 48, and 72 h. Cell viability was detected by an MTT assay. (D) MTT assay was conducted to determine the effect of Z-GP-DAVLBH on the viability of hFOB 1.19 cells. (E) Osteosarcoma cells (SJSA-1 and 143B) were treated with Z-GP-DAVLBH (50 nmol/L for SJSA-1 cells and 100 nmol/L for 143B cells) for 48 h in the presence or absence of TAL. Cell viability was detected by MTT assay. (F) Cell colony formation assay of SJSA-1 and 143B cells treated with the indicated concentrations of Z-GP-DAVLBH. Representative images of cell colonies are shown and clonogenicity was quantitated by normalization to the untreated group. Magnification: 100×. (G) The cell cycle distribution was detected by flow cytometry analysis. (H) Cell cycle-associated proteins were analyzed by Western blotting analysis. Data are presented as mean ± SEM, n = 3; ∗∗∗ P <0.001 vs. the untreated (0 nmol/L, 0.1% DMSO) group; ### P < 0.001 vs. the Z-GP-DAVLBH-treated group.
Fap α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fap α/product/R&D Systems
Average 94 stars, based on 1 article reviews
fap α - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Z-GP-DAVLBH inhibits the proliferation of osteosarcoma cells in vitro . (A) The protein levels of FAP α in SJSA-1, 143B, hFOB 1.19 cells, and HBVPs were determined by Western blotting analysis. (B) SJSA-1, 143B, hFOB 1.19 cells, and HBVPs were treated with Z-GP-DAVLBH (10 μmol/L) in the presence or absence of TAL for 2 h. The hydrolysis efficiency of Z-GP-DAVLBH was analyzed by LC–MS. HBVPs serve as an FAP α -negative control cells. ND, no detection. (C) Osteosarcoma cells (SJSA-1 and 143B) were treated with various concentrations of Z-GP-DAVLBH for 24, 48, and 72 h. Cell viability was detected by an MTT assay. (D) MTT assay was conducted to determine the effect of Z-GP-DAVLBH on the viability of hFOB 1.19 cells. (E) Osteosarcoma cells (SJSA-1 and 143B) were treated with Z-GP-DAVLBH (50 nmol/L for SJSA-1 cells and 100 nmol/L for 143B cells) for 48 h in the presence or absence of TAL. Cell viability was detected by MTT assay. (F) Cell colony formation assay of SJSA-1 and 143B cells treated with the indicated concentrations of Z-GP-DAVLBH. Representative images of cell colonies are shown and clonogenicity was quantitated by normalization to the untreated group. Magnification: 100×. (G) The cell cycle distribution was detected by flow cytometry analysis. (H) Cell cycle-associated proteins were analyzed by Western blotting analysis. Data are presented as mean ± SEM, n = 3; ∗∗∗ P <0.001 vs. the untreated (0 nmol/L, 0.1% DMSO) group; ### P < 0.001 vs. the Z-GP-DAVLBH-treated group.

Journal: Acta Pharmaceutica Sinica. B

Article Title: The FAP α -activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway

doi: 10.1016/j.apsb.2021.08.015

Figure Lengend Snippet: Z-GP-DAVLBH inhibits the proliferation of osteosarcoma cells in vitro . (A) The protein levels of FAP α in SJSA-1, 143B, hFOB 1.19 cells, and HBVPs were determined by Western blotting analysis. (B) SJSA-1, 143B, hFOB 1.19 cells, and HBVPs were treated with Z-GP-DAVLBH (10 μmol/L) in the presence or absence of TAL for 2 h. The hydrolysis efficiency of Z-GP-DAVLBH was analyzed by LC–MS. HBVPs serve as an FAP α -negative control cells. ND, no detection. (C) Osteosarcoma cells (SJSA-1 and 143B) were treated with various concentrations of Z-GP-DAVLBH for 24, 48, and 72 h. Cell viability was detected by an MTT assay. (D) MTT assay was conducted to determine the effect of Z-GP-DAVLBH on the viability of hFOB 1.19 cells. (E) Osteosarcoma cells (SJSA-1 and 143B) were treated with Z-GP-DAVLBH (50 nmol/L for SJSA-1 cells and 100 nmol/L for 143B cells) for 48 h in the presence or absence of TAL. Cell viability was detected by MTT assay. (F) Cell colony formation assay of SJSA-1 and 143B cells treated with the indicated concentrations of Z-GP-DAVLBH. Representative images of cell colonies are shown and clonogenicity was quantitated by normalization to the untreated group. Magnification: 100×. (G) The cell cycle distribution was detected by flow cytometry analysis. (H) Cell cycle-associated proteins were analyzed by Western blotting analysis. Data are presented as mean ± SEM, n = 3; ∗∗∗ P <0.001 vs. the untreated (0 nmol/L, 0.1% DMSO) group; ### P < 0.001 vs. the Z-GP-DAVLBH-treated group.

Article Snippet: The following antibodies were used at a dilution of 1:500–1:1000: p-AXL (Tyr779) (catalog AF2228) and FAP α (catalog AF3715) were obtained from R&D system (Minneapolis, MN, USA).

Techniques: In Vitro, Western Blot, Liquid Chromatography with Mass Spectroscopy, Negative Control, MTT Assay, Colony Assay, Flow Cytometry